Evidence map›Paper›PMID 33314801›Full record

ArticleBrain and behavior2021

Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high-dose pharmaceutical-grade biotin (MD1003).

Nicolas Collongues, Jens Kuhle, Charidimos Tsagkas, Julien Lamy, Nicolas Meyer, Christian Barro, Katrin Parmar, Michael Amann, Jens Wuerfel, Ludwig Kappos and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain and behavior, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Nicolas CollonguesDepartment of Neurology, University Hospital of Strasbourg, Strasbourg, France.ORCID 0000-0002-3683-5582
Jens KuhleNeurological Clinic and Polyclinic, Departments of Medicine, Clinical Research and Biomedical Engineering, University Hospital Basel, University of Basel, Basel, Switzerland.
Charidimos TsagkasNeurological Clinic and Polyclinic, Departments of Medicine, Clinical Research and Biomedical Engineering, University Hospital Basel, University of Basel, Basel, Switzerland.
Julien LamyICube, Université de Strasbourg-CNRS, University of Strasbourg, Strasbourg, France.
Nicolas MeyerGMRC, Service de Santé Publique, University Hospital of Strasbourg, Strasbourg, France.
Christian BarroUniversity of Basel, Basel, Switzerland.
Katrin ParmarNeurological Clinic and Polyclinic, Departments of Medicine, Clinical Research and Biomedical Engineering, University Hospital Basel, University of Basel, Basel, Switzerland.
Michael AmannMedical Image Analysis Centre Basel and Department of Biomedical Engineering, University of Basel, Basel, Switzerland.
Jens WuerfelMedical Image Analysis Centre Basel and Department of Biomedical Engineering, University of Basel, Basel, Switzerland.
Ludwig KapposNeurological Clinic and Polyclinic, Departments of Medicine, Clinical Research and Biomedical Engineering, University Hospital Basel, University of Basel, Basel, Switzerland.
Thibault MoreauDepartment of Neurology, University Hospital of Dijon, Dijon, France.
Jerome de SezeDepartment of Neurology, University Hospital of Strasbourg, Strasbourg, France.
University of Basel · CHUniversité de Strasbourg · FRCentre National de la Recherche Scientifique · FRMaison des Sciences sociales et des Humanités de Dijon · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh-dose pharmaceutical-grade biotin (MD1003) has positive effects on disability in progressive multiple sclerosis (PMS), but its mechanism of action remains unclear. The objective of our study was to quantify the effect of MD1003 in patients with PMS, using clinical response, plasma neurofilament light chain (pNfL) levels, and brain (BV) or cervical spinal cord volume (CSCV). MATERIALS AND

methodsForty-eight patients with PMS newly treated with MD1003 were followed during one year. Patients were assessed clinically using the Expanded Disability Status Scale (EDSS), the nine-hole peg test (9HPT), and the 25-foot walk time (25FWT). CSCV was quantified using CORDIAL software and BV using SIENA or SIENAX. We measured pNfL level using SIMOA at several time points. Bayesian linear and logistic regressions were used to evaluate potential prognostic factors.

resultsTreatment response, defined as a significant decrease of EDSS, 25FWT, or 9HPT at 1 year, was observed in 13 patients (27%). A gain of volume was noted in 7/24 patients for brain and in 10/19 patients for cervical spinal cord. The strongest predictors of poor treatment response were a high pNfL level at MD1003 onset (OR 0.96; 95% CI [0.91; 1]), high age at MS onset (OR 0.95; 95% CI [0.89; 1.01]), and an increase in brain lesion load during MD1003 treatment (OR 0.81; 95% CI [0.55; 1.05]).

conclusionsMD1003 treatment was associated with clinical, BV, and CSCV improvement at 1 year. The correlation between the levels of pNfL at baseline, the age at multiple sclerosis onset, and a treatment response at M12 is consistent with a better effect in less disabled patients.

Indexed as

Multiple SclerosisBayes TheoremBiomarkersBiotinDisability EvaluationDisease ProgressionHumansMagnetic Resonance ImagingBiomarkersBiotinbrain volumeMD1003multiple sclerosisneurofilament light chainprogressive formspinal cord volume

Identifiers

PMID33314801
PMCPMC7882156
OpenAlexW3112982228

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.